Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
Esperion Therapeutics, Inc. (ESPR)
A forensic read on Esperion Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-8.6
Altman Z-score
Clean
Earnings quality
4
Forensic signals
-59.5%
ROE
$816M
Market cap
Esperion Therapeutics, Inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is -8.6, placing it in the Distress zone. 4 forensic signals were flagged in its latest SEC filings, led by receivables vs revenue.
What the filings flag
127d DSOReceivables vs revenue.Days sales outstanding moved from 88 to 127 days FY2024→FY2025 (receivables +75% vs revenue +21%). Receivables are outrunning sales — a flag for aggressive revenue recognition or slipping collections.
-460%Return on invested capital.Return on invested capital is -460% and slipping from -383% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+71.0%/yrShare-count dilution.Diluted share count changed +213% over the last 3 years to FY2025 (+71.0%/yr). The count is GROWING — existing holders are being diluted. That's ~71.0% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~213%.
stoppedShareholder returns — halted.Capital returns have STOPPED — $55M of buybacks + dividends in FY2020, but ~$0 in FY2021. A halt usually means the company is conserving cash; understand why before reading it as neutral.
Key fundamentals
Net Margin-5.6%
Free Cash Flow$-13.1M
Latest Revenue$403.1M
Revenue Growth YoY+21.3%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Esperion Therapeutics, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about ESPR's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown